The full Federal Circuit last Friday overruled its own precedent in BMC Resources v Paymentech, which said that “in order for a party to be liable for induced infringement, some other single entity must be liable for direct infringement”.
Instead, the court said that “all the steps of a claimed method must be performed in order to find induced infringement, but that it is not necessary to prove that all the steps were committed by a single entity”.
That will make it much easier to enforce method claims where multiple actors perform individual steps. Such claims are increasingly unavoidable in e-commerce, cloud computing and personalised medicine patents.
In its amicus brief in the McKesson case last year, the Biotechnology Industry Organization said that “requiring patentees to structure claims so that they are incapable of being practiced by multiple actors to avoid this Court’s single entity rule is an unacceptable solution to address the divided infringement problem”.
Many personalised medicine and diagnostic method patents, for instance, involve doctors performing one step and clinical labs another. Under the old rule, there could be no infringement of such a patent unless one entity performed all the steps, or controlled or directed the other parties to perform them. “It’s hard to draft a patent claim that involves only one party and not the other,” said BIO’s deputy general counsel for IP, Hans Sauer.
The majority Federal Circuit opinion last week agreed with BIO that the rule was too restrictive, but it was hardly unanimous.
Judge Pauline Newman remained true to her opinion during the oral arguments that the law needs to be clearer. In her dissent, she faulted both the majority and the minority dissent for failing to clean up the mess the law has become. “This new rule simply imposes disruption, uncertainty, and disincentive upon the innovation communities,” wrote Newman.
The minority dissent, authored by Judge Richard Linn, said the majority went too far, effectively rewriting the statute governing induced patent infringement. “The majority opinion is rooted in its conception of what Congress ought to have done rather than what it did,” wrote Linn.
The widely varying views of the justices make the case ripe for Supreme Court review. The decision also did not address all of the issues presented, most significantly “whether direct infringement can be found when no single entity performs all of the claimed steps of the patent”.
This could indicate that there was a lack of agreement among the justices that forced the majority to change its opinion several times, which might also account for the length of time it took for a decision to be handed down. Oral arguments took place in November last year and the decision was expected early this year.
The divided court makes the chances of Supreme Court review even more likely. Although Limelight said in a statement that it is confident it will win under the new rule on remand to the district court, it or Epic may still petition the High Court to review the case. “I think Supreme Court review is possible,” said Sauer. “When you look at the case itself, it’s a fractured opinion on a very important question.”
However, Sauer said there has not been as much outcry from the opposition as one might expect for a case that the Supreme Court would be eager to take up.
Eric Guttag of the Eric Guttag IP Law Office said it may take some time, but the chances of Supreme Court review are high – and that could spell trouble for those who are happy about the decision.
“My Ouija board would suggest that the Supreme Court will adopt Judge Linn’s more stringent ‘one actor’ rule,” said Guttag. “The Supreme Court is frankly ‘patent hostile’ in the extreme.”
Finnegan acted for Akamai; Kirkland & Ellis acted for Limelight; King & Spalding acted for McKesson and Kilpatrick Stockton for Epic.